Welcome to our dedicated page for Clinuvl Phrmaceu news (Ticker: CLVLY), a resource for investors and traders seeking the latest updates and insights on Clinuvl Phrmaceu stock.
CLINUVEL Pharmaceuticals Ltd. reports news centered on photomedicine, melanocortin peptides and its American depositary receipt, CLVLY. Company updates frequently address SCENESSE (afamelanotide), including its established use in erythropoietic protoporphyria and clinical development as a systemic repigmentation therapy for vitiligo with narrowband ultraviolet B phototherapy.
Recurring developments also cover regulatory interactions with agencies such as the EMA and Health Canada, dermatology conference activity, preclinical work on sustained-release peptide formulations from CLINUVEL's VALLAURIX laboratories, and early research programs evaluating afamelanotide in additional disease areas. ADR-related updates may include foreign-issuer disclosure, program structure and U.S. market-access matters.
CLINUVEL PHARMACEUTICALS (ASX: CUV, Nasdaq: CUVL) reported its tenth consecutive annual profit for FY2026, with net profit after tax of $33.9 million (down 6% year-on-year) and revenues from ordinary activities of $94.0 million (down 1%), while total revenue plus other income reached $101.2 million.
Expenses edged down to $53.5 million, supporting a net profit before tax of $47.7 million, affected by unrealised foreign currency losses on US dollar term deposits. Cash reserves rose 12% to $252.1 million, net tangible assets per share increased to $5.35, and operating cash inflow was $36.9 million, enabling self-financed U.S. expansion.
The Board declared a fully franked $0.05 dividend per share for the ninth consecutive annual dividend, representing about 9% of FY2026 free cash generated, with ex-dividend on 3 September 2026 and payment on 18 September 2026.
CLINUVEL PHARMACEUTICALS (ASX: CUV, Nasdaq: CUVL) announced a strategic reorganisation, effective 1 January 2027, including relocating its corporate headquarters and key functions from Australia to the United States. The move aims to strengthen U.S. regulatory engagement, commercial partnerships, and access to deeper capital markets.
The company will reduce its global workforce by approximately 10%-20% and relocate selected functions to the U.S., aligning operating expenditure with current revenue and near-term clinical and commercial priorities. Operational resources will be focused exclusively on the U.S. pharmaceutical pipeline, notably late-stage programs in vitiligo, targeting an estimated six million U.S. patients.
According to CLINUVEL, over 66% of its shareholder register is foreign, with many investors in North America and Europe. Management cites higher valuation multiples for comparable U.S.-listed specialty pharma peers and the dominance of the U.S. in global pharmaceutical market value as key drivers of the strategic shift.
CLINUVEL PHARMACEUTICALS (ASX: CUV, Nasdaq planned: CUVL) announced that its American Depositary Share is expected to begin trading later today (New York time) on the Nasdaq Global Select Market under ticker CUVL, after the SEC declared its Form 20-F registration effective on 17 July and Nasdaq approved the listing.
The company’s over-the-counter ADR (CLVLY) will be upgraded from Level I to Level II, with each CUVL ADS representing one ordinary ASX-listed share. CLINUVEL does not plan to raise capital or issue new shares for this upgrade, and existing CLVLY holders need not take action. The company cautions that no final decision on the uplisting has been made and there is no guarantee trading will commence as expected.
Clinuvel (OTC:CLVLY) received a Health Canada Notice of Compliance for SCENESSE® (afamelanotide) to prevent phototoxicity in adult patients with erythropoietic protoporphyria (EPP), granting the company the right to market the drug in Canada under Sections C.08.002 and C.08.005 of the Food and Drug Regulations.
SCENESSE® is described as the only EPP treatment with marketing authorisation from any regulatory body, with prior approvals in Europe (2014), the US (2019) and Australia (2020). Five Canadian Specialty Centers are already trained and have treated EPP patients under special access. Over 21,000 doses have been administered globally, with some patients on therapy for up to 20 years, supporting a long-term safety profile.
CLINUVEL (OTC:CLVLY) received final EMA scientific advice on its pivotal Phase III CUV107 trial of SCENESSE® (afamelanotide) for non‑segmental vitiligo. The EMA endorsed a totality of evidence approach, photographic CFB assessment, primary endpoint T‑VASI50, secondary F‑VASI75, and prioritized darker skin types. CUV107 (n=300) is planned to start in 2H 2026 with five patient/physician surveys integrated.
CLINUVEL (OTC:CLVLY) showcased its photomedicine and vitiligo programs at AAD 2026, engaging over 20,000 dermatology delegates and drawing thousands to its Pavilion of Photomedicine.
Key clinical highlights included patient case reports from the Phase III CUV105 study showing repigmentation after 20 weeks of afamelanotide plus NB-UVB and maintained pigmentation up to a six-month follow-up in darker skin types. The Company also reported > 314,000 unique users reached digitally and introduced an AI-driven Vitiligo Visual Algorithm for objective pigmentation tracking.
CLINUVEL (NASDAQ:CLVLY) has announced significant progress in its development of novel sustained-release liquid drug formulations, marking a milestone after 10 years of research at its Singapore-based VALLAURIX laboratories. The company is advancing to a preclinical program focused on evaluating various drug release profiles.
The innovative formulations aim to extend the duration of peptide drug release, particularly melanocortins, with biocompatible delivery systems that allow flexible dosing through adjustable injection volumes. This advancement could benefit patients across different age groups and body weights. The preclinical program for the initial formulations is expected to complete in H2 2026.
CLINUVEL (CLVLY) has announced plans to upgrade its Level I American Depository Receipt (ADR) program to a Level II ADR and uplist to the Nasdaq Stock Market by the end of 2025. The company has initiated preparations to file Form 20-F with the SEC and has appointed U.S. legal counsel and an investment bank.
Currently, 28% of CLINUVEL's shares are held by U.S.-based investors, with the Level I ADR program representing approximately 7% of outstanding shares. The Bank of New York Mellon is proposed as the depositary. Importantly, the company's primary listing on the Australian Securities Exchange (ASX) will remain unchanged, and no capital raising is planned in connection with the uplisting.
CLINUVEL (CLVLY) has achieved its recruitment target of 200 patients for its Phase III trial (CUV105) evaluating SCENESSE® (afamelanotide 16mg) in vitiligo patients. The study, conducted across 37 sites in three continents with 57% of patients from the US, focuses on adolescent and adult patients with darker skin types (Fitzpatrick III-VI).
The trial compares SCENESSE® administered every three weeks plus narrowband ultraviolet B (NB-UVB) phototherapy against NB-UVB monotherapy alone over a 20-week treatment period with a 6-month follow-up. Initial results are expected in 2H 2026. Early clinical observations from five case studies show promising repigmentation results, including a notable case of a skin type V patient with 20-year vitiligo history showing improvement in arm and leg lesions.
CLINUVEL is set to make its debut at the American Academy of Dermatology (AAD) Annual Meeting from March 7-11, 2025, featuring a 4,800-square-foot Pavilion of Photomedicine. The exhibition will showcase the company's innovative melanocortin technology and development program for SCENESSE® (afamelanotide) in treating vitiligo.
The pavilion includes five curated courts highlighting CLINUVEL's innovations, a 360° video installation of patient perspectives, and the 'Derma Hall of Fame' featuring over 60 photomedicine pioneers. The exhibition will also present CLINUVEL's 20-year journey in developing SCENESSE®, the first FDA-approved treatment for erythropoietic protoporphyria (EPP).
The company is currently conducting a global phase III trial (CUV105) evaluating SCENESSE® as an adjunct to narrowband ultraviolet B phototherapy for vitiligo patients aged 12 and above with Fitzpatrick Skin Types III-VI. The AAD Meeting, attracting 20,000 delegates, represents the world's largest gathering of dermatology professionals.